APO Research
Talk to an analyst

APO RESEARCH · REPORT

First in Class (FIC) Antibody Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global First in Class (FIC) Antibody Drugs Industry Growth and Trends Forecast to 2032

23 December 2025125 pages

Choose your research edition.

Industry ResearchFirst in Class (FIC) Antibody Drugs Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal First in Class (FIC) Antibody Drugs Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal First in Class (FIC) Antibody Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal First in Class (FIC) Antibody Drugs Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal First in Class (FIC) Antibody Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global First in Class (FIC) Antibody Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for First in Class (FIC) Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for First in Class (FIC) Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for First in Class (FIC) Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of First in Class (FIC) Antibody Drugs include Suzhou Zejing Biopharmaceutical, Foreseen Biotechnology, Shenzhen Yipusheng, Suzhou Yilian Biopharmaceutical, Beijing Hotgen Biotech, Johnson & Johnson, Lixin Pharmaceutical Technology, Akeso, Inc and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global First in Class (FIC) Antibody Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The First in Class (FIC) Antibody Drugs market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global First in Class (FIC) Antibody Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to First in Class (FIC) Antibody Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global First in Class (FIC) Antibody Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

First in Class (FIC) Antibody Drugs Market by Company

Suzhou Zejing Biopharmaceutical

Foreseen Biotechnology

Shenzhen Yipusheng

Suzhou Yilian Biopharmaceutical

Beijing Hotgen Biotech

Johnson & Johnson

Lixin Pharmaceutical Technology

Akeso, Inc

Pfizer

Jiangsu Hengrui Medicine

GSK

Shanghai Henlius Biotech, Inc.

Dizal Pharma

AstraZeneca

Vertex Pharmaceuticals

Truqap

Telix

Talvey

Skyclary

Regeneron Pharmaceuticals

Pumis Biotechnology (BioNTech)

Ogsiveo

Merus

Lytgobi

Litfulo

Immatics

Fabhalta

Bicara Therapeutics

Bayer Corporation

Arvinas

First in Class (FIC) Antibody Drugs Segment by Type

Large Molecule FIC Drugs

Small Molecule FIC Drugs

First in Class (FIC) Antibody Drugs Segment by Application

Tumors and Cancers

Nervous System Diseases

Others

First in Class (FIC) Antibody Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global First in Class (FIC) Antibody Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of First in Class (FIC) Antibody Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of First in Class (FIC) Antibody Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of First in Class (FIC) Antibody Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of First in Class (FIC) Antibody Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Large Molecule FIC Drugs Table 2. Major Company of Small Molecule FIC Drugs Table 3. Global First in Class (FIC) Antibody Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 5. Global First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Type (2021-2026) Table 6. Global First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (US$ Million) Table 7. Global First in Class (FIC) Antibody Drugs Sales Market Share in Value by Type (2021-2026) Table 8. Global First in Class (FIC) Antibody Drugs Price by Type (2021-2026) & (USD/unit) Table 9. Global First in Class (FIC) Antibody Drugs Sales by Type (2027-2032) & (k units) Table 10. Global First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Type (2027-2032) Table 11. Global First in Class (FIC) Antibody Drugs Sales by Type (2027-2032) & (US$ Million) Table 12. Global First in Class (FIC) Antibody Drugs Sales Market Share in Value by Type (2027-2032) Table 13. Global First in Class (FIC) Antibody Drugs Price by Type (2027-2032) & (USD/unit) Table 14. North America First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 15. North America First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (US$ Million) Table 16. Europe First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 17. Europe First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 21. Latin America First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. First in Class (FIC) Antibody Drugs Industry Trends Table 25. First in Class (FIC) Antibody Drugs Industry Drivers Table 26. First in Class (FIC) Antibody Drugs Industry Opportunities and Challenges Table 27. First in Class (FIC) Antibody Drugs Industry Restraints Table 28. Global First in Class (FIC) Antibody Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Company (2021-2026) Table 30. Global First in Class (FIC) Antibody Drugs Sales by Company (2021-2026) & (k units) Table 31. Global First in Class (FIC) Antibody Drugs Sales Share by Company (2021-2026) Table 32. Global First in Class (FIC) Antibody Drugs Market Price by Company (2021-2026) & (USD/unit) Table 33. Global First in Class (FIC) Antibody Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global First in Class (FIC) Antibody Drugs Major Company Production Sites and Headquarters Table 35. Global First in Class (FIC) Antibody Drugs Company, Product Type & Application Table 36. Global First in Class (FIC) Antibody Drugs Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global First in Class (FIC) Antibody Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global First in Class (FIC) Antibody Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global First in Class (FIC) Antibody Drugs Sales by Region (2021-2026) & (k units) Table 41. Global First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Region (2021-2026) Table 42. Global First in Class (FIC) Antibody Drugs Sales by Region (2021-2026) & (US$ Million) Table 43. Global First in Class (FIC) Antibody Drugs Sales Market Share in Value by Region (2021-2026) Table 44. Global First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 45. Global First in Class (FIC) Antibody Drugs Sales by Region (2027-2032) & (k units) Table 46. Global First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Region (2027-2032) Table 47. Global First in Class (FIC) Antibody Drugs Sales by Region (2027-2032) & (US$ Million) Table 48. Global First in Class (FIC) Antibody Drugs Sales Market Share in Value by Region (2027-2032) Table 49. Global First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2027-2032) Table 50. Global First in Class (FIC) Antibody Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 52. Global First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Application (2021-2026) Table 53. Global First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (US$ Million) Table 54. Global First in Class (FIC) Antibody Drugs Sales Market Share in Value by Application (2021-2026) Table 55. Global First in Class (FIC) Antibody Drugs Price by Application (2021-2026) & (USD/unit) Table 56. Global First in Class (FIC) Antibody Drugs Sales by Application (2027-2032) & (k units) Table 57. Global First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Application (2027-2032) Table 58. Global First in Class (FIC) Antibody Drugs Sales by Application (2027-2032) & (US$ Million) Table 59. Global First in Class (FIC) Antibody Drugs Sales Market Share in Value by Application (2027-2032) Table 60. Global First in Class (FIC) Antibody Drugs Price by Application (2027-2032) & (USD/unit) Table 61. North America First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 62. North America First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (US$ Million) Table 63. Europe First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 64. Europe First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 68. Latin America First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Suzhou Zejing Biopharmaceutical Company Information Table 72. Suzhou Zejing Biopharmaceutical Business Overview Table 73. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio Table 75. Suzhou Zejing Biopharmaceutical Recent Development Table 76. Foreseen Biotechnology Company Information Table 77. Foreseen Biotechnology Business Overview Table 78. Foreseen Biotechnology First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. Foreseen Biotechnology First in Class (FIC) Antibody Drugs Product Portfolio Table 80. Foreseen Biotechnology Recent Development Table 81. Shenzhen Yipusheng Company Information Table 82. Shenzhen Yipusheng Business Overview Table 83. Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Product Portfolio Table 85. Shenzhen Yipusheng Recent Development Table 86. Suzhou Yilian Biopharmaceutical Company Information Table 87. Suzhou Yilian Biopharmaceutical Business Overview Table 88. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio Table 90. Suzhou Yilian Biopharmaceutical Recent Development Table 91. Beijing Hotgen Biotech Company Information Table 92. Beijing Hotgen Biotech Business Overview Table 93. Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Product Portfolio Table 95. Beijing Hotgen Biotech Recent Development Table 96. Johnson & Johnson Company Information Table 97. Johnson & Johnson Business Overview Table 98. Johnson & Johnson First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Johnson & Johnson First in Class (FIC) Antibody Drugs Product Portfolio Table 100. Johnson & Johnson Recent Development Table 101. Lixin Pharmaceutical Technology Company Information Table 102. Lixin Pharmaceutical Technology Business Overview Table 103. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Product Portfolio Table 105. Lixin Pharmaceutical Technology Recent Development Table 106. Akeso, Inc Company Information Table 107. Akeso, Inc Business Overview Table 108. Akeso, Inc First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Akeso, Inc First in Class (FIC) Antibody Drugs Product Portfolio Table 110. Akeso, Inc Recent Development Table 111. Pfizer Company Information Table 112. Pfizer Business Overview Table 113. Pfizer First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Pfizer First in Class (FIC) Antibody Drugs Product Portfolio Table 115. Pfizer Recent Development Table 116. Jiangsu Hengrui Medicine Company Information Table 117. Jiangsu Hengrui Medicine Business Overview Table 118. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Product Portfolio Table 120. Jiangsu Hengrui Medicine Recent Development Table 121. GSK Company Information Table 122. GSK Business Overview Table 123. GSK First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. GSK First in Class (FIC) Antibody Drugs Product Portfolio Table 125. GSK Recent Development Table 126. Shanghai Henlius Biotech, Inc. Company Information Table 127. Shanghai Henlius Biotech, Inc. Business Overview Table 128. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Product Portfolio Table 130. Shanghai Henlius Biotech, Inc. Recent Development Table 131. Dizal Pharma Company Information Table 132. Dizal Pharma Business Overview Table 133. Dizal Pharma First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Dizal Pharma First in Class (FIC) Antibody Drugs Product Portfolio Table 135. Dizal Pharma Recent Development Table 136. AstraZeneca Company Information Table 137. AstraZeneca Business Overview Table 138. AstraZeneca First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. AstraZeneca First in Class (FIC) Antibody Drugs Product Portfolio Table 140. AstraZeneca Recent Development Table 141. Vertex Pharmaceuticals Company Information Table 142. Vertex Pharmaceuticals Business Overview Table 143. Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio Table 145. Vertex Pharmaceuticals Recent Development Table 146. Truqap Company Information Table 147. Truqap Business Overview Table 148. Truqap First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 149. Truqap First in Class (FIC) Antibody Drugs Product Portfolio Table 150. Truqap Recent Development Table 151. Telix Company Information Table 152. Telix Business Overview Table 153. Telix First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 154. Telix First in Class (FIC) Antibody Drugs Product Portfolio Table 155. Telix Recent Development Table 156. Talvey Company Information Table 157. Talvey Business Overview Table 158. Talvey First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 159. Talvey First in Class (FIC) Antibody Drugs Product Portfolio Table 160. Talvey Recent Development Table 161. Skyclary Company Information Table 162. Skyclary Business Overview Table 163. Skyclary First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 164. Skyclary First in Class (FIC) Antibody Drugs Product Portfolio Table 165. Skyclary Recent Development Table 166. Regeneron Pharmaceuticals Company Information Table 167. Regeneron Pharmaceuticals Business Overview Table 168. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 169. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio Table 170. Regeneron Pharmaceuticals Recent Development Table 171. Pumis Biotechnology (BioNTech) Company Information Table 172. Pumis Biotechnology (BioNTech) Business Overview Table 173. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 174. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Product Portfolio Table 175. Pumis Biotechnology (BioNTech) Recent Development Table 176. Ogsiveo Company Information Table 177. Ogsiveo Business Overview Table 178. Ogsiveo First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 179. Ogsiveo First in Class (FIC) Antibody Drugs Product Portfolio Table 180. Ogsiveo Recent Development Table 181. Merus Company Information Table 182. Merus Business Overview Table 183. Merus First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 184. Merus First in Class (FIC) Antibody Drugs Product Portfolio Table 185. Merus Recent Development Table 186. Lytgobi Company Information Table 187. Lytgobi Business Overview Table 188. Lytgobi First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 189. Lytgobi First in Class (FIC) Antibody Drugs Product Portfolio Table 190. Lytgobi Recent Development Table 191. Litfulo Company Information Table 192. Litfulo Business Overview Table 193. Litfulo First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 194. Litfulo First in Class (FIC) Antibody Drugs Product Portfolio Table 195. Litfulo Recent Development Table 196. Immatics Company Information Table 197. Immatics Business Overview Table 198. Immatics First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 199. Immatics First in Class (FIC) Antibody Drugs Product Portfolio Table 200. Immatics Recent Development Table 201. Fabhalta Company Information Table 202. Fabhalta Business Overview Table 203. Fabhalta First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 204. Fabhalta First in Class (FIC) Antibody Drugs Product Portfolio Table 205. Fabhalta Recent Development Table 206. Bicara Therapeutics Company Information Table 207. Bicara Therapeutics Business Overview Table 208. Bicara Therapeutics First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 209. Bicara Therapeutics First in Class (FIC) Antibody Drugs Product Portfolio Table 210. Bicara Therapeutics Recent Development Table 211. Bayer Corporation Company Information Table 212. Bayer Corporation Business Overview Table 213. Bayer Corporation First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 214. Bayer Corporation First in Class (FIC) Antibody Drugs Product Portfolio Table 215. Bayer Corporation Recent Development Table 216. Arvinas Company Information Table 217. Arvinas Business Overview Table 218. Arvinas First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 219. Arvinas First in Class (FIC) Antibody Drugs Product Portfolio Table 220. Arvinas Recent Development Table 221. North America First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 222. North America First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 223. North America First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2026) Table 224. North America First in Class (FIC) Antibody Drugs Sales Forecast by Country (2027-2032) & (k units) Table 225. North America First in Class (FIC) Antibody Drugs Sales Market Share Forecast by Country (2027-2032) Table 226. North America First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 227. North America First in Class (FIC) Antibody Drugs Market Size by Country (2021-2026) & (US$ Million) Table 228. North America First in Class (FIC) Antibody Drugs Market Share by Country (2021-2026) Table 229. North America First in Class (FIC) Antibody Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 230. North America First in Class (FIC) Antibody Drugs Market Share Forecast by Country (2027-2032) Table 231. Europe First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 232. Europe First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 233. Europe First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2026) Table 234. Europe First in Class (FIC) Antibody Drugs Sales Forecast by Country (2027-2032) & (k units) Table 235. Europe First in Class (FIC) Antibody Drugs Sales Market Share Forecast by Country (2027-2032) Table 236. Europe First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 237. Europe First in Class (FIC) Antibody Drugs Market Size by Country (2021-2026) & (US$ Million) Table 238. Europe First in Class (FIC) Antibody Drugs Market Share by Country (2021-2026) Table 239. Europe First in Class (FIC) Antibody Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 240. Europe First in Class (FIC) Antibody Drugs Market Share Forecast by Country (2027-2032) Table 241. Asia-Pacific First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 242. Asia-Pacific First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 243. Asia-Pacific First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2026) Table 244. Asia-Pacific First in Class (FIC) Antibody Drugs Sales Forecast by Country (2027-2032) & (k units) Table 245. Asia-Pacific First in Class (FIC) Antibody Drugs Sales Market Share Forecast by Country (2027-2032) Table 246. Asia-Pacific First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 247. Asia-Pacific First in Class (FIC) Antibody Drugs Market Size by Country (2021-2026) & (US$ Million) Table 248. Asia-Pacific First in Class (FIC) Antibody Drugs Market Share by Country (2021-2026) Table 249. Asia-Pacific First in Class (FIC) Antibody Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 250. Asia-Pacific First in Class (FIC) Antibody Drugs Market Share Forecast by Country (2027-2032) Table 251. Latin America First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 252. Latin America First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 253. Latin America First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2026) Table 254. Latin America First in Class (FIC) Antibody Drugs Sales Forecast by Country (2027-2032) & (k units) Table 255. Latin America First in Class (FIC) Antibody Drugs Sales Market Share Forecast by Country (2027-2032) Table 256. Latin America First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 257. Latin America First in Class (FIC) Antibody Drugs Market Size by Country (2021-2026) & (US$ Million) Table 258. Latin America First in Class (FIC) Antibody Drugs Market Share by Country (2021-2026) Table 259. Latin America First in Class (FIC) Antibody Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 260. Latin America First in Class (FIC) Antibody Drugs Market Share Forecast by Country (2027-2032) Table 261. Middle East and Africa First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 262. Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 263. Middle East and Africa First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2026) Table 264. Middle East and Africa First in Class (FIC) Antibody Drugs Sales Forecast by Country (2027-2032) & (k units) Table 265. Middle East and Africa First in Class (FIC) Antibody Drugs Sales Market Share Forecast by Country (2027-2032) Table 266. Middle East and Africa First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 267. Middle East and Africa First in Class (FIC) Antibody Drugs Market Size by Country (2021-2026) & (US$ Million) Table 268. Middle East and Africa First in Class (FIC) Antibody Drugs Market Share by Country (2021-2026) Table 269. Middle East and Africa First in Class (FIC) Antibody Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 270. Middle East and Africa First in Class (FIC) Antibody Drugs Market Share Forecast by Country (2027-2032) Table 271. Key Raw Materials Table 272. Raw Materials Key Suppliers Table 273. First in Class (FIC) Antibody Drugs Distributors List Table 274. First in Class (FIC) Antibody Drugs Customers List Table 275. Research Programs/Design for This Report Table 276. Authors List of This Report Table 277. Secondary Sources Table 278. Primary Sources List of Figures Figure 1. First in Class (FIC) Antibody Drugs Image Figure 2. Global First in Class (FIC) Antibody Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global First in Class (FIC) Antibody Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global First in Class (FIC) Antibody Drugs Sales (2021-2032) & (k units) Figure 5. Large Molecule FIC Drugs Image Figure 6. Global Large Molecule FIC Drugs Sales YoY Growth (2021-2032) & (k units) Figure 7. Small Molecule FIC Drugs Image Figure 8. Global Small Molecule FIC Drugs Sales YoY Growth (2021-2032) & (k units) Figure 9. Global First in Class (FIC) Antibody Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global First in Class (FIC) Antibody Drugs Market Share by Type 2025 VS 2032 Figure 11. North America First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Type in 2025 Figure 12. North America First in Class (FIC) Antibody Drugs Sales Market Share in Value by Type in 2025 Figure 13. Europe First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Type in 2025 Figure 14. Europe First in Class (FIC) Antibody Drugs Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific First in Class (FIC) Antibody Drugs Sales Market Share in Value by Type in 2025 Figure 17. Latin America First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Latin America First in Class (FIC) Antibody Drugs Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa First in Class (FIC) Antibody Drugs Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 First in Class (FIC) Antibody Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Tumors and Cancers Image Figure 24. Global Tumors and Cancers Sales YoY Growth (2021-2032) & (k units) Figure 25. Nervous System Diseases Image Figure 26. Global Nervous System Diseases Sales YoY Growth (2021-2032) & (k units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 29. Global First in Class (FIC) Antibody Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global First in Class (FIC) Antibody Drugs Market Share by Application 2025 VS 2032 Figure 31. North America First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Application in 2025 Figure 32. North America First in Class (FIC) Antibody Drugs Sales Market Share in Value by Application in 2025 Figure 33. Europe First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Application in 2025 Figure 34. Europe First in Class (FIC) Antibody Drugs Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific First in Class (FIC) Antibody Drugs Sales Market Share in Value by Application in 2025 Figure 37. Latin America First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Latin America First in Class (FIC) Antibody Drugs Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa First in Class (FIC) Antibody Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa First in Class (FIC) Antibody Drugs Sales Market Share in Value by Application in 2025 Figure 41. North America First in Class (FIC) Antibody Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America First in Class (FIC) Antibody Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America First in Class (FIC) Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America First in Class (FIC) Antibody Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe First in Class (FIC) Antibody Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe First in Class (FIC) Antibody Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe First in Class (FIC) Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe First in Class (FIC) Antibody Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific First in Class (FIC) Antibody Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific First in Class (FIC) Antibody Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific First in Class (FIC) Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific First in Class (FIC) Antibody Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America First in Class (FIC) Antibody Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America First in Class (FIC) Antibody Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America First in Class (FIC) Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America First in Class (FIC) Antibody Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa First in Class (FIC) Antibody Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa First in Class (FIC) Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa First in Class (FIC) Antibody Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. First in Class (FIC) Antibody Drugs Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. First in Class (FIC) Antibody Drugs Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Large Molecule FIC Drugs
  • Small Molecule FIC Drugs
Applications
  • Tumors and Cancers
  • Nervous System Diseases
  • Others
Companies covered
  • Suzhou Zejing Biopharmaceutical
  • Foreseen Biotechnology
  • Shenzhen Yipusheng
  • Suzhou Yilian Biopharmaceutical
  • Beijing Hotgen Biotech
  • Johnson & Johnson
  • Lixin Pharmaceutical Technology
  • Akeso, Inc
  • Pfizer
  • Jiangsu Hengrui Medicine
  • GSK
  • Shanghai Henlius Biotech, Inc.
  • Dizal Pharma
  • AstraZeneca
  • Vertex Pharmaceuticals
  • Truqap
  • Telix
  • Talvey
  • Skyclary
  • Regeneron Pharmaceuticals
  • Pumis Biotechnology (BioNTech)
  • Ogsiveo
  • Merus
  • Lytgobi
  • Litfulo
  • Immatics
  • Fabhalta
  • Bicara Therapeutics
  • Bayer Corporation
  • Arvinas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global First in Class (FIC) Antibody Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global First in Class (FIC) Antibody Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 First in Class (FIC) Antibody Drugs Market by Type
  6. 1.3.1 Large Molecule FIC Drugs
  7. 1.3.2 Small Molecule FIC Drugs
  8. 1.4 Global First in Class (FIC) Antibody Drugs Market Size by Type
  9. 1.4.1 Global First in Class (FIC) Antibody Drugs Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global First in Class (FIC) Antibody Drugs Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global First in Class (FIC) Antibody Drugs Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America First in Class (FIC) Antibody Drugs Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe First in Class (FIC) Antibody Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific First in Class (FIC) Antibody Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America First in Class (FIC) Antibody Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa First in Class (FIC) Antibody Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 First in Class (FIC) Antibody Drugs Industry Trends
  2. 2.2 First in Class (FIC) Antibody Drugs Industry Drivers
  3. 2.3 First in Class (FIC) Antibody Drugs Industry Opportunities and Challenges
  4. 2.4 First in Class (FIC) Antibody Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by First in Class (FIC) Antibody Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by First in Class (FIC) Antibody Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by First in Class (FIC) Antibody Drugs Price (2021-2026)
  4. 3.4 Global First in Class (FIC) Antibody Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global First in Class (FIC) Antibody Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global First in Class (FIC) Antibody Drugs Company, Product Type & Application
  7. 3.7 Global First in Class (FIC) Antibody Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global First in Class (FIC) Antibody Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 First in Class (FIC) Antibody Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 First in Class (FIC) Antibody Drugs Tier 1, Tier 2, and Tier 3
4 First in Class (FIC) Antibody Drugs Regional Status and Outlook
  1. 4.1 Global First in Class (FIC) Antibody Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global First in Class (FIC) Antibody Drugs Historic Market Size by Region
  3. 4.2.1 Global First in Class (FIC) Antibody Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global First in Class (FIC) Antibody Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global First in Class (FIC) Antibody Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global First in Class (FIC) Antibody Drugs Forecasted Market Size by Region
  7. 4.3.1 Global First in Class (FIC) Antibody Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global First in Class (FIC) Antibody Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global First in Class (FIC) Antibody Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 First in Class (FIC) Antibody Drugs by Application
  1. 5.1 First in Class (FIC) Antibody Drugs Market by Application
  2. 5.1.1 Tumors and Cancers
  3. 5.1.2 Nervous System Diseases
  4. 5.1.3 Others
  5. 5.2 Global First in Class (FIC) Antibody Drugs Market Size by Application
  6. 5.2.1 Global First in Class (FIC) Antibody Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global First in Class (FIC) Antibody Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global First in Class (FIC) Antibody Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America First in Class (FIC) Antibody Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe First in Class (FIC) Antibody Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific First in Class (FIC) Antibody Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America First in Class (FIC) Antibody Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa First in Class (FIC) Antibody Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Suzhou Zejing Biopharmaceutical
  2. 6.1.1 Suzhou Zejing Biopharmaceutical Company Information
  3. 6.1.2 Suzhou Zejing Biopharmaceutical Business Overview
  4. 6.1.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio
  6. 6.1.5 Suzhou Zejing Biopharmaceutical Recent Developments
  7. 6.2 Foreseen Biotechnology
  8. 6.2.1 Foreseen Biotechnology Company Information
  9. 6.2.2 Foreseen Biotechnology Business Overview
  10. 6.2.3 Foreseen Biotechnology First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Foreseen Biotechnology First in Class (FIC) Antibody Drugs Product Portfolio
  12. 6.2.5 Foreseen Biotechnology Recent Developments
  13. 6.3 Shenzhen Yipusheng
  14. 6.3.1 Shenzhen Yipusheng Company Information
  15. 6.3.2 Shenzhen Yipusheng Business Overview
  16. 6.3.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Product Portfolio
  18. 6.3.5 Shenzhen Yipusheng Recent Developments
  19. 6.4 Suzhou Yilian Biopharmaceutical
  20. 6.4.1 Suzhou Yilian Biopharmaceutical Company Information
  21. 6.4.2 Suzhou Yilian Biopharmaceutical Business Overview
  22. 6.4.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio
  24. 6.4.5 Suzhou Yilian Biopharmaceutical Recent Developments
  25. 6.5 Beijing Hotgen Biotech
  26. 6.5.1 Beijing Hotgen Biotech Company Information
  27. 6.5.2 Beijing Hotgen Biotech Business Overview
  28. 6.5.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Product Portfolio
  30. 6.5.5 Beijing Hotgen Biotech Recent Developments
  31. 6.6 Johnson & Johnson
  32. 6.6.1 Johnson & Johnson Company Information
  33. 6.6.2 Johnson & Johnson Business Overview
  34. 6.6.3 Johnson & Johnson First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Johnson & Johnson First in Class (FIC) Antibody Drugs Product Portfolio
  36. 6.6.5 Johnson & Johnson Recent Developments
  37. 6.7 Lixin Pharmaceutical Technology
  38. 6.7.1 Lixin Pharmaceutical Technology Company Information
  39. 6.7.2 Lixin Pharmaceutical Technology Business Overview
  40. 6.7.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Product Portfolio
  42. 6.7.5 Lixin Pharmaceutical Technology Recent Developments
  43. 6.8 Akeso, Inc
  44. 6.8.1 Akeso, Inc Company Information
  45. 6.8.2 Akeso, Inc Business Overview
  46. 6.8.3 Akeso, Inc First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Akeso, Inc First in Class (FIC) Antibody Drugs Product Portfolio
  48. 6.8.5 Akeso, Inc Recent Developments
  49. 6.9 Pfizer
  50. 6.9.1 Pfizer Company Information
  51. 6.9.2 Pfizer Business Overview
  52. 6.9.3 Pfizer First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Pfizer First in Class (FIC) Antibody Drugs Product Portfolio
  54. 6.9.5 Pfizer Recent Developments
  55. 6.10 Jiangsu Hengrui Medicine
  56. 6.10.1 Jiangsu Hengrui Medicine Company Information
  57. 6.10.2 Jiangsu Hengrui Medicine Business Overview
  58. 6.10.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Product Portfolio
  60. 6.10.5 Jiangsu Hengrui Medicine Recent Developments
  61. 6.11 GSK
  62. 6.11.1 GSK Company Information
  63. 6.11.2 GSK Business Overview
  64. 6.11.3 GSK First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 GSK First in Class (FIC) Antibody Drugs Product Portfolio
  66. 6.11.5 GSK Recent Developments
  67. 6.12 Shanghai Henlius Biotech, Inc.
  68. 6.12.1 Shanghai Henlius Biotech, Inc. Company Information
  69. 6.12.2 Shanghai Henlius Biotech, Inc. Business Overview
  70. 6.12.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Product Portfolio
  72. 6.12.5 Shanghai Henlius Biotech, Inc. Recent Developments
  73. 6.13 Dizal Pharma
  74. 6.13.1 Dizal Pharma Company Information
  75. 6.13.2 Dizal Pharma Business Overview
  76. 6.13.3 Dizal Pharma First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Dizal Pharma First in Class (FIC) Antibody Drugs Product Portfolio
  78. 6.13.5 Dizal Pharma Recent Developments
  79. 6.14 AstraZeneca
  80. 6.14.1 AstraZeneca Company Information
  81. 6.14.2 AstraZeneca Business Overview
  82. 6.14.3 AstraZeneca First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 AstraZeneca First in Class (FIC) Antibody Drugs Product Portfolio
  84. 6.14.5 AstraZeneca Recent Developments
  85. 6.15 Vertex Pharmaceuticals
  86. 6.15.1 Vertex Pharmaceuticals Company Information
  87. 6.15.2 Vertex Pharmaceuticals Business Overview
  88. 6.15.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio
  90. 6.15.5 Vertex Pharmaceuticals Recent Developments
  91. 6.16 Truqap
  92. 6.16.1 Truqap Company Information
  93. 6.16.2 Truqap Business Overview
  94. 6.16.3 Truqap First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Truqap First in Class (FIC) Antibody Drugs Product Portfolio
  96. 6.16.5 Truqap Recent Developments
  97. 6.17 Telix
  98. 6.17.1 Telix Company Information
  99. 6.17.2 Telix Business Overview
  100. 6.17.3 Telix First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Telix First in Class (FIC) Antibody Drugs Product Portfolio
  102. 6.17.5 Telix Recent Developments
  103. 6.18 Talvey
  104. 6.18.1 Talvey Company Information
  105. 6.18.2 Talvey Business Overview
  106. 6.18.3 Talvey First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Talvey First in Class (FIC) Antibody Drugs Product Portfolio
  108. 6.18.5 Talvey Recent Developments
  109. 6.19 Skyclary
  110. 6.19.1 Skyclary Company Information
  111. 6.19.2 Skyclary Business Overview
  112. 6.19.3 Skyclary First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Skyclary First in Class (FIC) Antibody Drugs Product Portfolio
  114. 6.19.5 Skyclary Recent Developments
  115. 6.20 Regeneron Pharmaceuticals
  116. 6.20.1 Regeneron Pharmaceuticals Company Information
  117. 6.20.2 Regeneron Pharmaceuticals Business Overview
  118. 6.20.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio
  120. 6.20.5 Regeneron Pharmaceuticals Recent Developments
  121. 6.21 Pumis Biotechnology (BioNTech)
  122. 6.21.1 Pumis Biotechnology (BioNTech) Company Information
  123. 6.21.2 Pumis Biotechnology (BioNTech) Business Overview
  124. 6.21.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Product Portfolio
  126. 6.21.5 Pumis Biotechnology (BioNTech) Recent Developments
  127. 6.22 Ogsiveo
  128. 6.22.1 Ogsiveo Company Information
  129. 6.22.2 Ogsiveo Business Overview
  130. 6.22.3 Ogsiveo First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Ogsiveo First in Class (FIC) Antibody Drugs Product Portfolio
  132. 6.22.5 Ogsiveo Recent Developments
  133. 6.23 Merus
  134. 6.23.1 Merus Company Information
  135. 6.23.2 Merus Business Overview
  136. 6.23.3 Merus First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Merus First in Class (FIC) Antibody Drugs Product Portfolio
  138. 6.23.5 Merus Recent Developments
  139. 6.24 Lytgobi
  140. 6.24.1 Lytgobi Company Information
  141. 6.24.2 Lytgobi Business Overview
  142. 6.24.3 Lytgobi First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Lytgobi First in Class (FIC) Antibody Drugs Product Portfolio
  144. 6.24.5 Lytgobi Recent Developments
  145. 6.25 Litfulo
  146. 6.25.1 Litfulo Company Information
  147. 6.25.2 Litfulo Business Overview
  148. 6.25.3 Litfulo First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Litfulo First in Class (FIC) Antibody Drugs Product Portfolio
  150. 6.25.5 Litfulo Recent Developments
  151. 6.26 Immatics
  152. 6.26.1 Immatics Company Information
  153. 6.26.2 Immatics Business Overview
  154. 6.26.3 Immatics First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Immatics First in Class (FIC) Antibody Drugs Product Portfolio
  156. 6.26.5 Immatics Recent Developments
  157. 6.27 Fabhalta
  158. 6.27.1 Fabhalta Company Information
  159. 6.27.2 Fabhalta Business Overview
  160. 6.27.3 Fabhalta First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  161. 6.27.4 Fabhalta First in Class (FIC) Antibody Drugs Product Portfolio
  162. 6.27.5 Fabhalta Recent Developments
  163. 6.28 Bicara Therapeutics
  164. 6.28.1 Bicara Therapeutics Company Information
  165. 6.28.2 Bicara Therapeutics Business Overview
  166. 6.28.3 Bicara Therapeutics First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  167. 6.28.4 Bicara Therapeutics First in Class (FIC) Antibody Drugs Product Portfolio
  168. 6.28.5 Bicara Therapeutics Recent Developments
  169. 6.29 Bayer Corporation
  170. 6.29.1 Bayer Corporation Company Information
  171. 6.29.2 Bayer Corporation Business Overview
  172. 6.29.3 Bayer Corporation First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  173. 6.29.4 Bayer Corporation First in Class (FIC) Antibody Drugs Product Portfolio
  174. 6.29.5 Bayer Corporation Recent Developments
  175. 6.30 Arvinas
  176. 6.30.1 Arvinas Company Information
  177. 6.30.2 Arvinas Business Overview
  178. 6.30.3 Arvinas First in Class (FIC) Antibody Drugs Sales, Revenue and Gross Margin (2021-2026)
  179. 6.30.4 Arvinas First in Class (FIC) Antibody Drugs Product Portfolio
  180. 6.30.5 Arvinas Recent Developments
7 North America by Country
  1. 7.1 North America First in Class (FIC) Antibody Drugs Sales by Country
  2. 7.1.1 North America First in Class (FIC) Antibody Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America First in Class (FIC) Antibody Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America First in Class (FIC) Antibody Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America First in Class (FIC) Antibody Drugs Market Size by Country
  6. 7.2.1 North America First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America First in Class (FIC) Antibody Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America First in Class (FIC) Antibody Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe First in Class (FIC) Antibody Drugs Sales by Country
  2. 8.1.1 Europe First in Class (FIC) Antibody Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe First in Class (FIC) Antibody Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe First in Class (FIC) Antibody Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe First in Class (FIC) Antibody Drugs Market Size by Country
  6. 8.2.1 Europe First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe First in Class (FIC) Antibody Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe First in Class (FIC) Antibody Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific First in Class (FIC) Antibody Drugs Sales by Country
  2. 9.1.1 Asia-Pacific First in Class (FIC) Antibody Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific First in Class (FIC) Antibody Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific First in Class (FIC) Antibody Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific First in Class (FIC) Antibody Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific First in Class (FIC) Antibody Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific First in Class (FIC) Antibody Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America First in Class (FIC) Antibody Drugs Sales by Country
  2. 10.1.1 South America First in Class (FIC) Antibody Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America First in Class (FIC) Antibody Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America First in Class (FIC) Antibody Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America First in Class (FIC) Antibody Drugs Market Size by Country
  6. 10.2.1 South America First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America First in Class (FIC) Antibody Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America First in Class (FIC) Antibody Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Country
  2. 11.1.1 Middle East and Africa First in Class (FIC) Antibody Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa First in Class (FIC) Antibody Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa First in Class (FIC) Antibody Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa First in Class (FIC) Antibody Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa First in Class (FIC) Antibody Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa First in Class (FIC) Antibody Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 First in Class (FIC) Antibody Drugs Value Chain Analysis
  2. 12.1.1 First in Class (FIC) Antibody Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 First in Class (FIC) Antibody Drugs Production Mode & Process
  7. 12.2 First in Class (FIC) Antibody Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 First in Class (FIC) Antibody Drugs Distributors
  10. 12.2.3 First in Class (FIC) Antibody Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst